Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones

NCT ID: NCT01533389

Last Updated: 2013-11-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 114 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-10-31
• Study Completion Date: 2012-08-31

Brief Summary

A lower ureteral calculus, which measures 5 millimeters and less, may be easily expelled by symptomatic therapy. Actually, it has about a 50% chance of successful expulsion.

However, a complication such as urinary tract infection or hydronephrosis or persistent pain may occur before it is expelled. Thus, it is imperative to minimize the occurrence of complications in the process of expectant treatment and also to reduce the time required to expel calculi.

Pharmacotherapy is to relieve ureteral obstruction and thus to expel urinary calculi easily.

This clinical trial is to evaluate the efficacy of silodosin, a selective α1A-blocker, on calculous expulsion in expectant treatment for patients with lower and mid ureteral calculi.

Detailed Description

Lower and mid ureteral calculi, accounting for approximately 70% of ureteral calculi, has a high chance of successful treatment thanks to ureteroscopic lithotripsy or extracorporeal shock wave lithotripsy (ESWL)1-3), but at the same time have problems of postprocedural complications and high expenses4). A lower ureteral calculus, which measures 5 millimeters and less, may be easily expelled by symptomatic therapy. Actually, it has about a 50% chance of successful expulsion5). However, a complication such as urinary tract infection or hydronephrosis or persistent pain may occur before it is expelled. Thus, it is imperative to minimize the occurrence of complications in the process of expectant treatment and also to reduce the time required to expel calculi.

It has been recently reported that pharmacotherapy is adhibited to the expulsion of urinary calculi and the relief of pain. The migration of ureteral calculi is influenced by both the calculus and the ureter. In the case of the calculus, size, shape, number and location influence it. In regard to the ureter, it is significantly influenced by the cramp of the ureteral smooth muscle, the edema of the ureteral submucosa, the pain caused by the calculus and the activities of adrenoreceptors6).

Pharmacotherapy is to relieve ureteral obstruction and thus to expel urinary calculi easily. Ureteral obstruction, caused by urinary calculi, obtunds ureteral peristalsis but strengthens ureteral contraction, which may cause urinary retention or regurgitation7-8). In this connection, studies have been conducted as to methods to reduce abnormal urinary reaction caused by urinary calculi and to smoothen uroflow. Currently, hormone drugs including hydroxyprogesterone, prostaglandin synthetase inhibitors, calcium-channel antagonists, α1-blockers and steroid drugs are used to expel urinary calculi and to suppress pain. The guidelines on urinary calculi, drawn up in 2007, recommend using α-blockers as they are superior to other drugs in efficacy9-12).

The drug to be used in this clinical trial, silodosin, was registered under the proprietary name of 'THRUPAS® Capsule 4mg' and is being marketed after being authorized by Korea Food and Drug Administration (FDA), which selectively acts on the α1A-adrenoreceptor.

This clinical trial is to evaluate the efficacy of silodosin, a selective α1A-blocker, on calculous expulsion in expectant treatment for patients with lower and mid ureteral calculi.

Conditions

Ureteral Stone

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Silodosin

8mg QD

Group Type: EXPERIMENTAL

Silodosin

Intervention Type: DRUG

Drug: silodosin dosage form : capsule dosage : placebo 4mg*2 (8mg) frequency and duration : QD, 4weeks

Arms: Placebo

Placebo

8mg QD

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks

Interventions

Silodosin

Drug: silodosin dosage form : capsule dosage : placebo 4mg*2 (8mg) frequency and duration : QD, 4weeks

Arms: Placebo

Intervention Type: DRUG

Placebo

dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Males or female patients aged 20 and over
• Patients having ureteral calculi located mid or lower ureter on abdominal radiograms or excretory urograms or non-enhanced computed tomograms.
• Patients whose calculi measure 10 millimeters and less.
• Patients who voluntarily decided to take part in this clinical trial and gave written consent.

Exclusion Criteria

• Patients who do not want to undergo expectant treatment
• Female patients who are pregnant or nursing
• Patients with febrile urinary tract infection or severe hydronephrosis or ulcerative diseases or hypotension.
• Patients with severe hepatic dysfunction(e.g. hepatic failure, hepatic cirrhosis, icterus, hepatoma)
• Patients who take α-blocker or α/β-blockers or calcium-channel blockers or steroid drugs
• Patients with multiple ureteral calculi
• Patients whose urinary tracts are anatomically deformed or stenosed
• Patients who underwent invasive operations on their ureters before
• Patients whose blood creatinine levels are 2mg/dL and over
• Patients who are hypersensitive to silodosin
• Patients who take part in clinical trials other than this one
• Patients judged to be inappropriate for this clinical trial by investigators

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

JW Pharmaceutical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gwan-Joong Joo, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Kangbuk Samsung Hospital

Tae-Yoong Jeong, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Myongji Hospital

Young-Sik Kim, Ph.D

Role: PRINCIPAL_INVESTIGATOR

National Health Insurance Service Ilsan Hospital

Tak-Geun Yoo, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Eulji Central Hospital

Jae-Yong Jeong, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Inje University

Locations

NHIC Ilsan Hospital

Goyang-si, Gyonggi-Do, South Korea

Myongji Hospital

Goyang-si, Gyonggi-Do, South Korea

Kangbuk Samsung Medical Center

Seoul, Seoul, South Korea

Inje Univ. Sanggye Paik Hospital

Seoul, Seoul, South Korea

Eulji General Hospital

Seoul, Seoul, South Korea

Countries

South Korea

Other Identifiers

CWP-SDS-404

Identifier Type: -

Identifier Source: org_study_id